Singapore’s Tourism Board And NATAS To Partner With The FinLab To Help Travel Agencies Evolve Through Digital Transformation

Source: https://www.opengovasia.com/articles/singapores-tourism-board-and-natas-to-partner-with-the-finlab-to-help-travel-agencies-evolve-through-digital-transformation

The Ministry of Communications and Information announced that The FinLab would be collaborating with the Singapore Tourism Board (STB) and the National Association of Travel Agents Singapore (NATAS) to help travel agencies evolve and renovate their businesses via a digital transformation programme for the selected businesses.

Singapore’s economy relies heavily on the tourism industry, which accounts for approximately four per cent of its annual gross domestic product. However, changing consumer behaviour and the growing competition for tourism dollars regionally pose a significant challenge to the industry.

Consequently, to ensure the industry’s continued growth, it is important for members of the industry to grasp the currently available opportunities in the online travel market, particularly those in the Asia Pacific online travel market, which is expected to grow by 13 per cent by focusing on technological transformation.

None the less, it was noted that despite most consumers moving to online booking sites, travel agencies retain the opportunity to go beyond the usual issuance of e-tickets and vouchers and, in addition to these services, provide consumers with more personalised services. Thus, travel agencies must understand how they can apply digital solutions to understand and connect more effectively with their target audience along with personal interaction.

In the face of a dynamic economic landscape in Singapore, travel agencies and the companies and initiatives that seek to help them grow and transform must remain constantly cognizant of the challenges that SMEs (small and medium-sized enterprises) face in harnessing the potential of technology and in transforming it into benefits for their businesses.

Experts maintain that in order for the travel industry to continue to capitalise on growth opportunities in the long-term it must continue to innovate. One avenue to do this is to collaborate with partners who have the expertise to assist Singapore’s travel agents in developing digital competencies.

The FinLab, a partnership between SGInnovate and United Overseas Bank (UOB), is a business accelerator formed to propel technology companies and catalyse the digital transformation of businesses.

The FinLab’s programme presents the selected Singaporean travel agencies the opportunity to not only connect to The Finlab’s ecosystem of associates to transform their business digitally but also enables them to use what they have learned to improve their business’ performance, enhance consumer experiences and seize business opportunities present in the digital economy.

Ms Ong Ling Lee, Director at Travel Agents and Tourist Guides, STB stated that their collaboration with The FinLab is one of several initiatives created to support travel agencies and help them grown and transform their businesses in an increasingly competitive tourism market. “We hope that with the practical guidance provided by this acceleration programme, travel agents will be encouraged to take the first step towards achieving their growth ambitions”, Ms Lee added.

Advertisements

United States Pediatric Vacccine Market Size by Top Key Players Like Sanofi Pasteur, GlaxoSmithKline(GSK), Merck & Co., Pfizer Inc and Grifols 2018 – 2025

United States pediatric vaccines market is expected to grow over US$ 15 Billion by 2025, driven by increased disease awareness, growing public acceptance, increasing government focus on immunization programs and increased government funding for the vaccines development.
“Pediatric Vaccines Market: United States Industry Analysis, Trends, Opportunity, Market Size and Segment Forecasts, 2018 – 2025” provides a unique tool for evaluating the market, highlighting opportunities, supporting strategic and tactical decision–making. This report recognizes that in this rapidly–evolving and competitive environment, up–to–date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments and focuses on United States pediatric vaccines market. The report also provides clear insight into current and future developments of the United States pediatric vaccines market. Furthermore, this report provides a deep and thorough evaluation of the top 10 pediatric vaccines by disease indication. On the basis of disease indication, the top 10 pediatric vaccines provide an in-depth analysis of doses administered, number of children being vaccinated and market size. The research includes historic data from 2010 to 2017 and forecasts until 2025.
The report also explores detailed description of growth drivers and inhibitors of the United States pediatric vaccines market.
The report concludes with the profiles of major players in the United States pediatric vaccines market. The key market players are evaluated on various parameters such as company overview, pediatric vaccines portfolios and latest development & trends of the pediatric vaccines market.
The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:
• Sanofi Pasteur
• GlaxoSmithKline(GSK)
• Merck & Co.
• Pfizer Inc
• Grifols
Major Pediatric Vaccines (Disease Indication) Covered Under This Report Are:
• Diphtheria, Tetanus & Pertussis (DTap)
• Hepatitis A
• Varicella/Chicken Pox
• Pneumococcal
• Haemophilus Influenzae Type B (HIB)
• Polio
• Rotavirus
• Hepatitis B
• Influenza Pediatric
• Measles, Mumps & Rubella (MMR)
The Latest Industry Data Included in this Report:
• United States Pediatric Vaccines Market Size & Analysis ,2010 – 2025
• United States Pediatric Vaccines Market Share and Y–o–Y Growth (%),2010 – 2025
• United States Pediatric Vaccines Market by Disease Indication ,2010 – 2025
• 10 Pediatric Vaccines Doses Administered (Volume),2010 – 2025
• Number of Children Being Vaccinated (Volume)2010 – 2025
• 10 Pediatric Vaccines Market Size and Forecast(Value),2010 – 2025
• Key Market Drivers and Inhibitors of the United States Pediatric Vaccines Market
• A Comprehensive List of Key Market Players Along with the Analysis of their Current
   Product Portfolios and Latest Recent Development and Trends
The Following Key Questions have been Addressed in the Report:
• What is the size of the United States pediatric vaccines market during 2010 -2025?
• How will each segment of the United States pediatric vaccines market grow
   during the forecast period and what will be the revenue generated
   by each of the segments by the end of 2025?
• Which major pediatric vaccines provides highest market share?
• How much number of children being vaccinated during 2010 – 2025?
• How are the overall market and segments types growing?
• What are the major market drivers and inhibitors in the United States pediatric vaccines market?
• Who are the key players in the United States pediatric vaccines market and
   what are their contributions?

Global Non Invasive Prenatal Testing Market Analysis, Top Companies, New Technology, Demand and Opportunity Analysis

Global Non-Invasive Prenatal Testing(NIPT) market is anticipated to grow over US$ 2.5 Billion by 2025 with an impressive double-digit growth rate in the forecast period 2018 – 2025. 
The market is driven by number of factors such as high incidence rate of babies born with down syndrome, no risk of miscarriage with NIPT test, shifting trend towards child bearing at advanced maternal age (35 years or older), rising focus on reimbursement for NIPT and increasing preference for non-invasive techniques over invasive methods.
“Global Non-Invasive Prenatal Testing Market: Demand, Insights, Analysis, Opportunities, Growth Potential and Forecast 2018 – 2025” presents an in-depth assessment of the Global Non-Invasive Prenatal Testing (NIPT) market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for Global Non-Invasive Prenatal Testing (NIPT). The research includes historic data from 2014 to 2017 and forecasts until 2025.
The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, NIPT test volume, revenues and provides forecasts through 2025. A comprehensive analysis has been done on market share of NIPT tests and Countries-based market. The report also includes assessment of comparative test analysis by companies. Additionally, the report includes insights into the Global perspectives on clinical adoption of NIPT. Key trends in terms of collaboration, partnership, merger & acquisition, venture capital investment, distribution and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Non-Invasive Prenatal Testing (NIPT) market.
The report concludes with the profiles of major players in the Global Non-Invasive Prenatal Testing (NIPT) market. The key market players are evaluated on various parameters such as company overview, NIPT test portfolios and latest development and trends of the Non-Invasive Prenatal Testing (NIPT) market.
Key Findings:
• United States is anticipated to be the most attractive market in the Global Non-Invasive Prenatal Testing(NIPT) market
• China NIPT test market is set to cross USD 400 Million by 2025
• Panorama test accounted for the highest share in Global Non-Invasive Prenatal Testing(NIPT) market
• Verifi test has the second highest revenue share in the Global Non-Invasive Prenatal Testing(NIPT) market
• Rising focus on Reimbursement for NIPT test will revolutionize the market
• Two–Child policy is likely to boost China NIPT market
The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:
 
Illumina, Natera, Sequenom Laboratories (LabCorp), Ariosa Diagnostics (Roche), BGI Diagnosis Co. Ltd, Berry Genomics, Quest Diagnostics, LifeCodexx AG, Premaitha Health, NIPD Genetics
Major and Promising Non-Invasive Prenatal Testing (NIPT) Covered Under This Report are:
Panorama, MaterniT21 PLUS, Harmony, Verifi, NIFTY, IONA, PrenaTest, Bambni, Veracity and Other Tests
Major Countries Analyzed Under This Report are:
United States, China, Japan, India, Brazil, Australia, New Zealand, United Kingdom, Germany, Italy, Spain, France, Switzerland, Sweden, Belgium, Russia, Turkey, Netherland, Poland, Armenia, Moldova, Denmark and Rest of the Countries.
The Latest Industry Data Included in this Report:
• Global Non–Invasive Prenatal Testing Market Volume & Future Trends (2014 – 2025)
• Global Non–Invasive Prenatal Testing Market Revenue & Future Trends (2014 – 2025)
• Global Non–Invasive Prenatal Testing Market Share and Y–o–Y Growth (%)
• Market Share Analysis, by Test, 2014 – 2025 (%)
• Market Share Analysis, by Major Countries, 2014 – 2025 (%)
• Global Non–Invasive Prenatal Testing Market, By Test (Volume and Value),2011 – 2025
• Global Non–Invasive Prenatal Testing Market, By Geography (Volume and Value),2014 – 2025
• Non–Invasive Prenatal Testing(NIPT) Comparative Analysis – By Test
• Major Deals in Global Non–Invasive Prenatal Testing Market
• Global Perspectives on Clinical Adoption of NIPT
• Global Non–Invasive Prenatal Testing Market Drivers and Inhibitors
• Key Companies Analysis

United States Insulin Delivery Market Competitive Landscape, Changing Market Trends and Emerging Opportunities

Single User License

$900.00

United States Insulin Delivery Devices Market is anticipated to surpass US$ 6 Billion by 2022.
Growth in US insulin delivery devices market can be attributed to factors such as increasing number of diabetic patients, growing awareness towards diabetes, user–friendly design, help avoid over/under–dosing of insulin, improved glucose control and flexible, lifestyle-compatible treatment options and technological advancement in insulin delivery devices.
Browse full table of contents and data tables at : http://www.dpiresearch.com/report-details.php?P_ID=120
The report titled “United States Insulin Delivery Devices Market Outlook 2017: Key Product Categories (Insulin Pumps, Insulin Pens (Reusable, Disposable) Demand, Insights, Analysis, Opportunities, Segmentation and Forecast to 2022” examines the market dynamics, competitive landscape and discusses major trends. The study describes an in–depth analysis of the United States insulin pump and insulin pen market.
The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, volume, revenues and provides forecasts through 2022. A comprehensive analysis has been done on market share of insulin delivery devices segment.
The report provides an in-depth analysis of the type 1, type 2 and newly diagnosed type 1 diabetes and overall diabetes population in United States. It provides essential insights into total insulin delivery users, insulin pump users and insulin pen users with more focused–on reusable and prefilled insulin pen users.
The report further sheds light on detailed US reimbursement scenario of insulin pump and insulin pen. Additionally, the report includes assessment of preferred insulin pump brand by the patients. The report also explores detailed description of growth drivers and inhibitors of the United States insulin delivery market.
The report concludes with the profiles of major players in the insulin delivery devices market such as Insulet Corporation, Medtronic, Roche, Tandem Diabetes Care, Novo Nordisk, Eli Lilly, Sanofi, Owen Mumford. The major market players are evaluated on various parameters such as company overview, product portfolios and latest development and trends of the insulin delivery devices market.
Key Highlights of the United States Insulin Delivery Devices Market Report: 
• Diabetes Population (2011 – 2022)
• Overall Insulin Delivery Users Snapshot (2011 – 2022)
• Insulin Pump Users (2011 – 2022)
• Type 1 Diabetes Insulin Pump Users (2011 – 2022)
• Type 2 Diabetes Insulin Pump Users (2011 – 2022)
• Insulin Pen Users (2011 – 2022)
• Reusable (Cartridge) Insulin Pen Users (2011 – 2022)
• Prefilled (Disposable) Insulin Pen Users (2011 – 2022)
• Insulin Pen Segment – (Reusable & Prefilled Insulin Pen) Users Share (2011 – 2022)
• Overall Insulin Delivery Devices:  Market Snapshot (2011 – 2022)
• Insulin Pump Market Size (2011 – 2022)
• Insulin Pen Market Size (2011 – 2022)
• Reusable (Cartridge) Insulin Pen Market (2011 – 2022)
• Prefilled (Disposable) Insulin Pen Market (2011 – 2022)
• Insulin Delivery Devices Segment (Insulin Pump & Insulin Pen) Market Share (2011 – 2022)
• Insulin Pen Segment – (Reusable & Prefilled Insulin Pen) Market Share (2011 – 2022)
• Insulin Pump Preferred Brand – By Product (2011 – 2022)
• Insulin Pump and Pen Reimbursement Scenario (2011 – 2022)
• Key Drivers and Inhibitors of the Insulin Delivery Devices Market
• Key Companies Analysis
The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:
• Insulet Corporation
• Medtronic
• Roche
• Tandem Diabetes Care
• Novo Nordisk
• Eli Lilly
• Sanofi
• Owen Mumford
Key Deliverables in the Study
• Market Definition for the specified topic along with identification of key drivers and inhibitors for the market
• Trending factors influencing the market shares of the United States Insulin Delivery Devices
• It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
• It provides a five-year forecast which helps to provide a long-term assessment of developments in the United States Insulin Delivery Devices Market.
• Identification and Analysis of the Macro and Micro factors that affect the United States Insulin Delivery Devices Market
• Identification of factors instrumental in changing the market scenarios, rising prospective opportunities
• A comprehensive list of key market players along with the analysis of their current product portfolios and recent development

United States Proton Therapy Market Research Report 2018, Market Overview and Forecast up to 2025

Single User License

$900.00

United States Proton Therapy market is expected to reach nearly US$ 1 Billion, potentially US$ 7 Billion by 2025.
Market growth can be attributed to factors such as rising cancer incidence, increasing number of proton therapy centers, decreasing cost of proton therapy treatment, technological advances and market adoption. However, high costs involved in the establishment of the center is likely to restrain growth in the forecast period.
Browse full table of contents and data tables at : http://www.dpiresearch.com/report-details.php?P_ID=119
The research report titled “United States Proton Therapy Market: Demand, Insights, Analysis, Opportunities, Growth Potential and Forecast 2018 – 2025” examines the market dynamics, competitive landscape and discusses major trends. The study describes an in–depth analysis of the United States actual and potential proton therapy market.
The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, volume, revenues and provides forecasts through 2025. A comprehensive analysis has been done on market share of US proton therapy center (installed base) and treatment room by company. The report also provides information on the proton therapy current applications and comparative analysis with more focused on pros and cons of proton therapy and competitive analysis of eight companies.
The report further sheds light on the number of treatment rooms, current and upcoming proton therapy centers. In addition, the report also provides essential insights on number of patients treated at US proton therapy centers from 2008 to 2015.
The report also includes assessment of US reimbursement scenario, proton therapy clinical trials and offers a clear view of the proton therapy center component analysis. Key trends in terms of venture capital investment, collaborations, partnerships, licensing and development agreements are analyzed with details.  The report also explores detailed description of growth drivers and inhibitors of the US proton therapy market.
The report concludes with the profiles of major players in the US proton therapy market. The key market players are evaluated on various parameters such as company overview, product portfolio, US proton therapy centers developed by the companies and recent development & trends of the proton therapy market.
Key Highlights of the United States Proton Therapy Market Report: 
• Proton Therapy Current Applications
• Pros and Cons of Proton Therapy, Radiotherapy and Carbon Ion Therapy
• Proton Therapy Competitive Analysis: By Company
• Market Size & Analysis: United States Proton Therapy (2012 – 2025)
• Market Opportunity Assessment: United States Proton Therapy (2012 – 2025)
• United States Number of Treatment Rooms and Forecast (2012 – 2025)
• United States Proton Therapy Center (Installed Base) and Treatment Room Market Share: By Company
• United States Proton Therapy Center Infrastructure Analysis: Treatment Rooms & Proton Therapy Accelerator
• United States Number of Patients Treated at Proton Therapy Centers (2008 – 2015)
• United States Proton Therapy Reimbursement Scenario
• Proton Therapy Center Component Analysis
• Proton Therapy Clinical Trail Insight by Phase, Institute & Country
• Proton Therapy Market – Major Deals
• Key Market Drivers and Inhibitors of the United States Proton Therapy Market
• Major Companies Analysis
Key Companies Covered in the Report are as follows:
• Optivus
• Hitachi
• Ion Beam Applications(IBA)
• Varian Medical Systems
• Mevion Medical Systems

United States Flu Vaccine Market: Research Industry Analysis, Size, Sales and Forecast By 2024

Single User License

$900.00

United States flu vaccine market is expected to reach nearly US$ 3 Billion by 2024.
 
Growth in US flu vaccine market can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against flu vaccine and introduction of quadrivalent flu vaccine.
Browse full table of contents and data tables at : http://www.dpiresearch.com/report-details.php?P_ID=110
Long–term Growth Projection and Development:
• Sanofi to Acquire Protein Sciences Corporation
 
• It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024
 
• Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season
 
• It is projected that GSK flu vaccine sales value will reach around US$ 1.5 Billion by 2024
 
• BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine
“Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024” provides a deep and thorough evaluation of the United States flu vaccine market. The report provides an in–depth analysis of the flu vaccination pattern in both Children and Adults in the United States. It also provides essential insights into flu vaccine production, price, consumption, supply, distribution, demand and specification. It also covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials and promising flu vaccines in the clinical development. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the US flu vaccine market such as Sanofi Pasteur, GSK and Seqirus. The major market players are evaluated on various parameters such as company overview, product outlook, latest development & trends and sales analysis of flu vaccine market from 2011 to 2022. The report also entails major drivers and inhibitors in the US flu vaccine market.
Key Topics Covered in the Report
• Market Overview: United States Flu Vaccine Market (2010 –  2024)
• United States Number of Persons Vaccinated with Flu Vaccine (2010 – 2024)
• United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification
• Reimbursement & Regulatory System in the US Flu Vaccine Market
• Mergers, Acquisitions, Key Agreements & Collaborations
• Promising Flu Vaccine in Clinical Development
• Flu Vaccine Clinical Trial Insights by Phase, Company & Country
• Key Drivers and Inhibitors of the US Flu Vaccine Market
• Key Companies Analysis
Major Flu Vaccines Covered Under This Report Are:
• Fluzone High–Dose
• Fluzone Quadrivalent
• Intradermal (ID) Trivalent
•Vaxigrip
• Fluarix Quadrivalent
• Flulaval Quadrivalent
• Flucelvax Quadrivalent
• Afluria Quadrivalent
• Agrippal
• Fluad
• Fluvirin
• Fluvax
Key Companies Covered in This Report:
• Seqirus
• Sanofi Pasteur
• GlaxoSmithKline(GSK)

GSK to Compensate for Merck’s Pediatric HepB Vaccine Shortage

Source: https://www.aafp.org/

Merck & Co. Inc. has announced that because of a continuing manufacturing issue, its shortage of pediatric hepatitis B (HepB) recombinant vaccine (Recombivax HB) will continue through the rest of 2018.

On its Current Vaccine Shortages & Delays webpage,(www.cdc.gov) the CDC said GlaxoSmithKline will mitigate the shortage of pediatric HepB vaccines with supply to meet full demand in the United States.

GSK will do so using its monovalent pediatric HepB vaccine (Engerix-B Pediatric) and its diphtheria, tetanus toxoids and acellular pertussis (DTaP); HepB; and inactivated polio vaccine (IPV) pediatric combination vaccine (Pediarix).

Merck hasn’t distributed its pediatric HepB vaccine since mid-2017 and has informed the CDC that it will have only a limited supply available for the rest of the year.

The combined supply from the two manufacturers should account for about 90 percent of the amount of monovalent pediatric HepB vaccine normally available for the rest of 2018, said the CDC.

Visit for More Reports on Pediatric Vaccine: http://www.dpiresearch.com/http://www.dpiresearch.com/